Indian markets ended the week on a weak note, with the BSE 500 index down 0.8% as 347 stocks saw declines up to 12% WoW, led by IT, power, and FMCG sectors. FII selling and cautious investor sentiment continued to pressure the market, while DIIs partially cushioned the fall.
The BSE Smallcap index fell 1.5% this week, with 76% of stocks in the red. However, 20 smallcap stocks bucked the trend, delivering weekly gains up to 56%, highlighting strong investor interest and selective bullish momentum in the segment.
ETMutualFunds selected 10 funds from five equity mutual fund categories. Investors should choose mutual funds based on their goals, investment horizons, and risk profiles.
InCred Equities has reshuffled its high-conviction stock list, adding Tata Steel, VRL Logistics, and GE Vernova T&D, while dropping Bajaj Auto, Skipper, and NTPC amid festive demand and GST-driven consumption recovery.
Grey market trends indicate potential listing gains of 422% for nine upcoming IPOs next week, including Lenskart, PhysicsWallah, and Groww, reflecting strong investor interest and market momentum across new-age and SME listings.
Growws Rs 6,632 crore IPO saw strong demand, with 17.6 times overall subscription. Investors can check allotment status via MUFG Intime India or BSE. Refunds and share credits begin November 11, with listing on BSE and NSE scheduled for November 12.
Zerodha LIQUIDCASE, Indias first liquid ETF with a growth NAV, has reached nearly Rs 6,000 crore in AUM within two years of its January 2024 launch. Founder Nithin Kamath said the growth is entirely organic, driven by investors seeking a simple, tax-efficient alternative to traditional liquid funds.
HSBC sees India as a safe haven amid global AI market excitement. Indian stocks are currently underrepresented in emerging market portfolios. Increased investment could significantly benefit India. HSBC is positive on Indian equities, setting a 2026 Sensex target of 94,000. Valuations are now less of a concern. India offers value compared to Chinese equities.
In a remarkable financial turn, Torrent Pharmaceuticals has disclosed a staggering 30% rise in after-tax profit for the September quarter, reaching 591 crore. This impressive growth is attributed to thriving sales in various markets, which escalated their total revenue to 3,302 crore.
